|
Oct 9
|
FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts
|
|
Jul 29
|
FibroGen, Inc. (NASDAQ:FGEN) is a favorite amongst institutional investors who own 54%
|
|
Jun 3
|
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
|
|
Jun 3
|
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
|
|
Jun 3
|
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
|
|
May 8
|
FibroGen First Quarter 2024 Earnings: Beats Expectations
|
|
May 7
|
FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript
|
|
May 7
|
Q1 2024 FibroGen Inc Earnings Call
|
|
May 7
|
FibroGen to Participate in Upcoming Investor Conferences
|
|
May 7
|
FibroGen Inc (FGEN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...
|
|
May 6
|
FibroGen Reports First Quarter 2024 Financial Results
|
|
Apr 29
|
FibroGen to Report First Quarter 2024 Financial Results
|
|
Apr 24
|
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncolo...
|
|
Apr 23
|
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
|
|
Apr 16
|
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
|
|
Apr 16
|
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
|
|
Apr 12
|
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
|
|
Apr 12
|
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
|
|
Apr 8
|
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
|
|
Apr 6
|
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
|